Thomas Lars Andresen
Gründer bei Nanovi Radiotherapy A/S
Profil
Thomas Lars Andresen is the founder of MonTa Biosciences ApS, founded in 2014, and Nanovi Radiotherapy A, founded in 2012.
At Nanovi Radiotherapy A, he also holds the title of Director from 2012 to present.
Dr. Andresen's current job is as the Chief Executive Officer & Director at T-Cypher Bio Ltd.
since 2021.
He previously worked as the Head-Research & Development at LiPlasome Pharma A.
Dr. Andresen received his graduate and doctorate degrees from the Technical University of Denmark.
Dr. Andresen is also the founder of Torque Therapeutics, Inc.
Aktive Positionen von Thomas Lars Andresen
Unternehmen | Position | Beginn |
---|---|---|
Nanovi Radiotherapy A/S
Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark. | Gründer | 01.01.2012 |
T-Cypher Bio Ltd.
T-Cypher Bio Ltd. Miscellaneous Commercial ServicesCommercial Services T-Cypher Bio Ltd. is a British biotechnology company. The company was founded in 2015. Thomas Lars Andresen has been the CEO of the company since 2021. | Vorstandsvorsitzender | 01.08.2021 |
Ehemalige bekannte Positionen von Thomas Lars Andresen
Unternehmen | Position | Ende |
---|---|---|
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | Gründer | - |
MonTa Biosciences ApS
MonTa Biosciences ApS BiotechnologyHealth Technology MonTa Biosciences ApS engages in research and development in biotechnology for cancer immunotherapy. Its technology offers a solution to deliver immune stimulating compounds directly to immune cells in the blood. The company was founded by Thomas Lars Andresen, Jonas Henriksen, and Simon Skjøde Jensen in August 2014 and is headquartered in Brønshøj, Denmark. | Gründer | - |
LiPlasome Pharma A/S
LiPlasome Pharma A/S Pharmaceuticals: MajorHealth Technology LiPlasome Pharma A/S develops, produces and supplies drugs for chemotherapy treatment. It has developed a technology based on incapsulation of chemotherapy in liposomes (fatty molecules) that will only dissolve in and around cancer tissue (tumors or metastases). The firm’s technology will improve chemotherapy treatment within a wide range of cancer diseases significantly as it improves the balance between effect and side effects. LiPlasome’s first drug candicate LiplaCis which is a liposonal formulation of Cisplatin, is in clinical phase 1. The company was founded in January 2001 by Ole Gunner Mouritsen and is headquartered in Hoersholm, Denmark. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Thomas Lars Andresen
Technical University of Denmark | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 5 |
---|---|
LiPlasome Pharma A/S
LiPlasome Pharma A/S Pharmaceuticals: MajorHealth Technology LiPlasome Pharma A/S develops, produces and supplies drugs for chemotherapy treatment. It has developed a technology based on incapsulation of chemotherapy in liposomes (fatty molecules) that will only dissolve in and around cancer tissue (tumors or metastases). The firm’s technology will improve chemotherapy treatment within a wide range of cancer diseases significantly as it improves the balance between effect and side effects. LiPlasome’s first drug candicate LiplaCis which is a liposonal formulation of Cisplatin, is in clinical phase 1. The company was founded in January 2001 by Ole Gunner Mouritsen and is headquartered in Hoersholm, Denmark. | Health Technology |
Nanovi Radiotherapy A/S
Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark. | Health Technology |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | Health Technology |
MonTa Biosciences ApS
MonTa Biosciences ApS BiotechnologyHealth Technology MonTa Biosciences ApS engages in research and development in biotechnology for cancer immunotherapy. Its technology offers a solution to deliver immune stimulating compounds directly to immune cells in the blood. The company was founded by Thomas Lars Andresen, Jonas Henriksen, and Simon Skjøde Jensen in August 2014 and is headquartered in Brønshøj, Denmark. | Health Technology |
T-Cypher Bio Ltd.
T-Cypher Bio Ltd. Miscellaneous Commercial ServicesCommercial Services T-Cypher Bio Ltd. is a British biotechnology company. The company was founded in 2015. Thomas Lars Andresen has been the CEO of the company since 2021. | Commercial Services |